Lomustine is an alkylating nitrosourea compound used in chemotherapy.
This drug has a highly lipid soluble drug, and thus crosses the blood brain, allowing it to be used for CNS lymphoma in dogs.
Dexamethasone has been reported to be ineffective in attenuating the neutropenia caused by lomustine in dogs.
Recommended dose is 2.84 mg/m2 orally once for a period of 3 - 6 months.
- Kristal O et al (2004) Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs. J Vet Intern Med 18:75–80
- Skorupski KA et al (2011) Prospective randomized clinical trial assessing the efficacy of Denamarin for prevention of CCNU-induced hepatopathy in tumor-bearing dogs. J Vet Intern Med 25(4):838-845
- Napalkov NP et al (1981) Transplacental carcinogenic effect of n-nitrosoethylurea in dogs. Cancer Lett 12(1-2):161-167
- Intile JL et al (2009) Evaluation of dexamethasone as a chemoprotectant for CCNU-induced bone marrow suppression in dogs. Vet Comp Oncol 7:69–77
- Tripp CD et al (2011) Tolerability of metronomic administration of lomustine in dogs with cancer. J Vet Intern Med 25(2):278-284